Clinical trial
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
NCT00338988 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00338988 |
|---|---|
| Title | Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma |
| Official title | A Phase II Study of Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma, Including Carcinoma of the Gallbladder and Biliary Tract |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Sanofi-Synthelabo Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer of the Gallbladder, Cancer of the Biliary Tract |
| Intervention type | Drug |
| Interventions | Capecitabine, Oxaliplatin |
| Enrollment | 44 |
| Start date | Aug 1, 2003 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Jun 20, 2006 |
| Last update posted | Aug 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: